Effects of oral methamphetamine on cocaine use: A randomized, double-blind, placebo-controlled trial

Drug and Alcohol Dependence

Volumn 101, Issue 1-2, 2009, Pages 34-41

  Mooney, Marc E ^a   Herin, David V ^a   Schmitz, Joy M ^b   Moukaddam, Nidal ^b   Green, Charles E ^b   Grabowski, John ^c  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

Agonist like treatment; Cocaine; Dextroamphetamine; Methamphetamine

Indexed keywords

METHAMPHETAMINE; PLACEBO;

ADULT; APPETITE; ARTICLE; BONE PAIN; CHILL; CLINICAL TRIAL; COCAINE DEPENDENCE; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; COUNSELING; DIARRHEA; DIZZINESS; DRUG EFFECT; DRUG EFFICACY; DRUG RELEASE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FEVER; HEART BEAT; HUMAN; MAJOR CLINICAL STUDY; MALE; MICTURITION; MYALGIA; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINORRHEA; SIDE EFFECT; SLEEP; URINALYSIS; WEIGHT; XEROSTOMIA;

ADOLESCENT; ADULT; AFFECT; BLOOD PRESSURE; BODY WEIGHT; CENTRAL NERVOUS SYSTEM STIMULANTS; COCAINE-RELATED DISORDERS; DELAYED-ACTION PREPARATIONS; DOUBLE-BLIND METHOD; FEMALE; HEART RATE; HUMANS; MALE; METHAMPHETAMINE; MIDDLE AGED; RIBOFLAVIN; SUBSTANCE ABUSE DETECTION; TREATMENT OUTCOME; YOUNG ADULT;

EID: 60249094085     PISSN: 03768716     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2008.10.016     Document Type: Article

References (54)

1. American Psychiatric Association, 1994. Diagnostic and statistical manual of mental disorders: DSM-IV. American Psychiatric Association, Washington, DC.
2. Anglin M.D., Burke C., Perrochet B., Stamper E., and Dawud-Noursi S. History of the methamphetamine problem. J. Psychoactive Drugs 32 (2000) 137-141
3. Barr A.M., Panenka W.J., MacEwan G.W., Thornton A.E., Lang D.J., Honer W.G., and Lecomte T. The need for speed: an update on methamphetamine addiction. J. Psychiatry Neurosci. 31 (2006) 301-313
4. Beck A., Ward C., Mendelson M., Mack J., and Erbaugh J. An inventory of measuring depression. Arch. Gen. Psychiatry 49 (1961) 599-608
5. Carroll K.M., Fenton L.R., Ball S.A., Nich C., Frankforter T.L., Shi J., and Rounsaville B.J. Efficacy of disulfiram and cognitive behavior therapy in cocaine-dependent outpatients: a randomized placebo-controlled trial. Arch. Gen. Psychiatry 61 (2004) 264-272
6. Carroll K.M., Kosten T.R., and Rounsaville B.J. Choosing a behavioral therapy platform for pharmacotherapy of substance users. Drug Alcohol Depend. 75 (2004) 123-134
7. Carroll K.M., and Rounsaville B.J. A vision of the next generation of behavioral therapies research in the addictions. Addiction 102 (2007) 850-862 discussion 863-859
8. Claxton A.J., Cramer J., and Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin. Ther. 23 (2001) 1296-1310
9. Comer S.D., Hart C.L., Ward A.S., Haney M., Foltin R.W., and Fischman M.W. Effects of repeated oral methamphetamine administration in humans. Psychopharmacology (Berl.) 155 (2001) 397-404
10. Del Boca F.K., Kranzler H.R., Brown J., and Korner P.F. Assessment of medication compliance in alcoholics through UV light detection of a riboflavin tracer. Alcohol Clin. Exp. Res. 20 (1996) 1412-1417
11. Dutra L., Stathopoulou G., Basden S.L., Leyro T.M., Powers M.B., and Otto M.W. A meta-analytic review of psychosocial interventions for substance use disorders. Am. J. Psychiatry 165 (2008) 179-187
12. First M.B., Spitzer R.L., Gibbon M., and Williams J.B. Structured Clinical Interview for DSM-VI Axis I Disorders-Patient Edition (SCID-I/P, Version 2.0) (1995), Biometric Research Department, NY
13. Glowa J.R., Rice K.C., Matecka D., and Rothman R.B. Phentermine/fenfluramine decreases cocaine self-administration in rhesus monkeys. Neuroreport 8 (1997) 1347-1351
14. Gorelick D.A., Gardner E.L., and Xi Z.X. Agents in development for the management of cocaine abuse. Drugs 64 (2004) 1547-1573
15. Grabowski J., Rhoades H., Schmitz J., Stotts A., Daruzska L.A., Creson D., and Moeller F.G. Dextroamphetamine for cocaine-dependence treatment: a double-blind randomized clinical trial. J. Clin. Psychopharmacol. 21 (2001) 522-526
16. Grabowski J., Rhoades H., Stotts A., Cowan K., Kopecky C., Dougherty A., Moeller F.G., Hassan S., and Schmitz J. Agonist-like or antagonist-like treatment for cocaine dependence with methadone for heroin dependence: two double-blind randomized clinical trials. Neuropsychopharmacology 29 (2004) 969-981
17. Grabowski J., Roache J.D., Schmitz J.M., Rhoades H., Creson D., and Korszun A. Replacement medication for cocaine dependence: methylphenidate. J. Clin. Psychopharmacol. 17 (1997) 485-488
18. Griffiths R.R., Brady J.V., and Snell J.D. Progressive-ratio performance maintained by drug infusions: comparison of cocaine, diethylpropion, chlorphentermine, and fenfluramine. Psychopharmacology (Berl.) 56 (1978) 5-13
19. Halikas J.A., Crosby R.D., Pearson V.L., and Graves N.M. A randomized double-blind study of carbamazepine in the treatment of cocaine abuse. Clin. Pharmacol. Ther. 62 (1997) 89-105
20. Hart C.L., Ward A.S., Haney M., Foltin R.W., and Fischman M.W. Methamphetamine self-administration by humans. Psychopharmacology (Berl.) 157 (2001) 75-81
21. Hart C.L., Ward A.S., Haney M., Nasser J., and Foltin R.W. Methamphetamine attenuates disruptions in performance and mood during simulated night-shift work. Psychopharmacology (Berl.) 169 (2003) 42-51
22. Higgins S.T., Delaney D.D., Budney A.J., Bickel W.K., Hughes J.R., Foerg F., and Fenwick J.W. A behavioral approach to achieving initial cocaine abstinence. Am. J. Psychiatry 148 (1991) 1218-1224
23. Johanson C.E., and Barrett J.E. The discriminative stimulus effects of cocaine in pigeons. J. Pharmacol. Exp. Ther. 267 (1993) 1-8
24. Lineberry T.W., and Bostwick J.M. Methamphetamine abuse: a perfect storm of complications. Mayo Clin. Proc. 81 (2006) 77-84
25. Margolin A., Kosten T.R., Avants S.K., Wilkins J., Ling W., Beckson M., Arndt I.O., Cornish J., Ascher J.A., Li S.H., et al. A multicenter trial of bupropion for cocaine dependence in methadone-maintained patients. Drug Alcohol Depend. 40 (1995) 125-131
26. Markowitz J.S., Straughn A.B., and Patrick K.S. Advances in the pharmacotherapy of attention-deficit-hyperactivity disorder: focus on methylphenidate formulations. Pharmacotherapy 23 (2003) 1281-1299
27. McDougle C.J., Black J.E., Malison R.T., Zimmermann R.C., Kosten T.R., Heninger G.R., and Price L.H. Noradrenergic dysregulation during discontinuation of cocaine use in addicts. Arch. Gen. Psychiatry 51 (1994) 713-719
28. McLellan A.T., Kushner H., Metzger D., Peters R., Smith I., Grissom G., Pettinati H., and Argeriou M. The Fifth Edition of the Addiction Severity Index. J. Subst. Abuse Treat. 9 (1992) 199-213
29. Micromedex® Healthcare Series, n.d. Retrieved June 9, 2008, http://www.thomsonhc.com. Thompson Healthcare, Greenwood Village, CO.
30. Mooney M.E., Schmitz J.M., Moeller F.G., and Grabowski J. Safety, tolerability and efficacy of levodopa-carbidopa treatment for cocaine dependence: two double-blind, randomized, clinical trials. Drug Alcohol Depend. 88 (2007) 214-223
31. Negus S.S., Mello N.K., Blough B.E., Baumann M.H., and Rothman R.B. Monoamine releasers with varying selectivity for dopamine/norepinephrine versus serotonin release as candidate "agonist" medications for cocaine dependence: studies in assays of cocaine discrimination and cocaine self-administration in rhesus monkeys. J. Pharmacol. Exp. Ther. 320 (2007) 627-636
32. Newman J.L., and Carroll M.E. Reinforcing effects of smoked methamphetamine in rhesus monkeys. Psychopharmacology (Berl.) 188 (2006) 193-200
33. Parasrampuria D.A., Schoedel K.A., Schuller R., Silber S.A., Ciccone P.E., Gu J., and Sellers E.M. Do formulation differences alter abuse liability of methylphenidate? A placebo-controlled, randomized, double-blind, crossover study in recreational drug users. J. Clin. Psychopharmacol. 27 (2007) 459-467
34. Perez-Reyes M., White W.R., McDonald S.A., Hicks R.E., Jeffcoat A.R., Hill J.M., and Cook C.E. Clinical effects of daily methamphetamine administration. Clin. Neuropharmacol. 14 (1991) 352-358
35. Petrakis I.L., Carroll K.M., Nich C., Gordon L.T., McCance-Katz E.F., Frankforter T., and Rounsaville B.J. Disulfiram treatment for cocaine dependence in methadone-maintained opioid addicts. Addiction 95 (2000) 219-228
36. Petry N.M., and Martin B. Low-cost contingency management for treating cocaine- and opioid-abusing methadone patients. J. Consult. Clin. Psychol. 70 (2002) 398-405
37. Petry N.M., Tedford J., Austin M., Nich C., Carroll K.M., and Rounsaville B.J. Prize reinforcement contingency management for treating cocaine users: how low can we go, and with whom?. Addiction 99 (2004) 349-360
38. Poling J., Oliveto A., Petry N., Sofuoglu M., Gonsai K., Gonzalez G., Martell B., and Kosten T.R. Six-month trial of bupropion with contingency management for cocaine dependence in a methadone-maintained population. Arch. Gen. Psychiatry 63 (2006) 219-228
39. Preston K.L., Umbricht A., Wong C.J., and Epstein D.H. Shaping cocaine abstinence by successive approximation. J. Consult. Clin. Psychol. 69 (2001) 643-654
40. Rothman R.B., Blough B.E., and Baumann M.H. Appetite suppressants as agonist substitution therapies for stimulant dependence. Ann. N. Y. Acad. Sci. 965 (2002) 109-126
41. Rothman R.B., Blough B.E., and Baumann M.H. Dual dopamine-5-HT releasers: potential treatment agents for cocaine addiction. Trends Pharmacol. Sci. 27 (2006) 612-618
42. Rothman R.B., Blough B.E., Woolverton W.L., Anderson K.G., Negus S.S., Mello N.K., Roth B.L., and Baumann M.H. Development of a rationally designed, low abuse potential, biogenic amine releaser that suppresses cocaine self-administration. J. Pharmacol. Exp. Ther. 313 (2005) 1361-1369
43. Rothman R.B., Partilla J.S., Dersch C.M., Carroll F.I., Rice K.C., and Baumann M.H. Methamphetamine dependence: medication development efforts based on the dual deficit model of stimulant addiction. Ann. N. Y. Acad. Sci. 914 (2000) 71-81
44. SAS Institute Inc., 2008. The SAS System for Windows. SAS Institute Inc., Cary, NC.
45. Schechter M.D., and McBurney D. Phentermine + fenfluramine produce cocaine-like discriminative cues. Life Sci. 59 (1996) PL303-308
46. Schmitz J.M., Mooney M.E., Moeller F.G., Stotts A.L., Green C., and Grabowski J. Levodopa pharmacotherapy for cocaine dependence: choosing the optimal behavioral therapy platform. Drug Alcohol Depend. 94 (2008) 142-150
47. Schmitz J.M., Stotts A.L., Rhoades H.M., and Grabowski J. Naltrexone and relapse prevention treatment for cocaine-dependent patients. Addict. Behav. 26 (2001) 167-180
48. Shearer J., Wodak A., van Beek I., Mattick R.P., and Lewis J. Pilot randomized double blind placebo-controlled study of dexamphetamine for cocaine dependence. Addiction 98 (2003) 1137-1141
49. Shoptaw S., Watson D.W., Reiber C., Rawson R.A., Montgomery M.A., Majewska M.D., and Ling W. Randomized controlled pilot trial of cabergoline, hydergine and levodopa/carbidopa: Los Angeles Cocaine Rapid Efficacy Screening Trial (CREST). Addiction 100 Suppl. 1 (2005) 78-90
50. Silverman K., Higgins S.T., Brooner R.K., Montoya I.D., Cone E.J., Schuster C.R., and Preston K.L. Sustained cocaine abstinence in methadone maintenance patients through voucher-based reinforcement therapy. Arch. Gen. Psychiatry 53 (1996) 409-415
51. Stitzer M.L., and Vandrey R. Contingency management: utility in the treatment of drug abuse disorders. Clin. Pharmacol. Ther. 83 (2008) 644-647
52. Villemagne V., Yuan J., Wong D.F., Dannals R.F., Hatzidimitriou G., Mathews W.B., Ravert H.T., Musachio J., McCann U.D., and Ricaurte G.A. Brain dopamine neurotoxicity in baboons treated with doses of methamphetamine comparable to those recreationally abused by humans: evidence from [11C]WIN-35,428 positron emission tomography studies and direct in vitro determinations. J. Neurosci. 18 (1998) 419-427
53. Wilkins J.N. Quantitative urine levels of cocaine and other substances of abuse. NIDA Res. Monogr. 175 (1997) 235-252
54. Wolfsohn R., Sanfilipo M., and Angrist B. A placebo-controlled trial of L-dopa/carbidopa in early cocaine abstinence. Neuropsychopharmacology 9 (1993) 49-53